A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Table 1 Dosing of ParvOryx in the current trial

Total dose	Study Time	Individual dose and route of administration	Duration
Dose level 1 (1 subject)
1E09 pfu	Day 1–4	1E08 pfu, intravenous infusion	2 h
1E09 pfu	Day 7	6E08 pfu, intrametastatic injection	As slowly as feasible
Dose level 2 (3 subjects)
5E09 pfu	Day 1–4	5E08 pfu, intravenous infusion	2 h
5E09 pfu	Day 7 or 10 or 14	3E09 pfu, intrametastatic injection	As slowly as feasible
Dose level 3 (3 subjects)
1E10 pfu	Day 1–4	1E09 pfu, intravenous infusion	2 h
1E10 pfu	Day 7 or 10 or 14	6E09 pfu, intrametastatic injection	As slowly as feasible

ISSN: 1471-2407